<DOC>
	<DOC>NCT01002664</DOC>
	<brief_summary>The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.</brief_summary>
	<brief_title>Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms</brief_title>
	<detailed_description>Eligible male subjects will be randomized to receive either MCS-2 or placebo for 12 weeks. Subjects are those not currently on any medicines for BPH or LUTS. During and at the end of the 12-week treatment period, randomized subjects will be evaluated for efficacy and safety parameters. All subjects will be advised to maintain a normal diet, similar to what was consumed before joining the study.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Age ≧ 40 years old. Not being treated for BPH or LUTS. PSA ≦ 4 ng/ml and no pathologicallyproven prostate cancer. IPSS ≥ 10 No known malignancy AST/ALT ≦ 3X UNL. Creatinine ≦ 3X UNL. Subjects who sign the informed consent form. Subjects' LUTS are not BPHrelated Have been treated with pelvis irradiation or pelvic surgery. Plan to undergo any invasive procedures within the study period. Active infection or inflammation. Considered ineligible by the investigators.</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Multi-carotenoids</keyword>
	<keyword>MCS-2</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
	<keyword>International prostate symptom scores</keyword>
</DOC>